Table 1. Demographic details for study cohort.
| Race | African American (AA) | Caucasian (CA) | p value |
|---|---|---|---|
| Number of subjects | n=55 | n=46 | |
| Gender (% male) | 60.0% | 73.91% | ns |
| Median Age (range) | 49 (34-70) | 48 (23-71) | 0.03 |
| Median Viral load (range) | 2.95 × 106 (0.035-19.5) | 2.145 × 106 (0.004-47.1) | ns |
| SVR (% positive) | 27.27% | 60.87% | <0.001 |
| Viral kinetics‡ | <0.001 | ||
| Poor$ | 58.0% | 27.27% | |
| Intermediate | 26.0% | 25.0% | |
| Marked | 16.0% | 47.73% | |
| IL-28B (rs12979860) genotype* | 0.005 | ||
| CC | 15.63% | 50.0% | |
| CT | 40.62% | 34.62% | |
| TT | 43.75% | 15.38% | |
| HCV genotype (1a/1b) | 33/22 | 36/10 | ns |
| Metavir Activity Score† (1-3) | ns | ||
| 1 | 18.52% | 26.09% | |
| 2 | 31.48% | 19.56% | |
| 3 | 50.0% | 54.35% | |
| Metavir Fibrosis Score† (0-4) | ns | ||
| 0 | 11.11% | 13.04% | |
| 1/2 | 74.07% | 69.57% | |
| 3/4 | 14.82% | 17.39% |
*
Twenty three AA and 21 CA subjects did not give permission for genetic analysis
†
One AA subject had no biopsy data recorded
‡
Viral kinetic data was not available for 5 AA and 2 CA subjects
ns=not significant